Cardiome Pharma Corp. (CRME) Forms $1.59 Double Bottom; Xencor (XNCR) Has 0.9 Sentiment

January 4, 2018 - By Martha Paddon

Cardiome Pharma Corp. (CRME) formed double bottom with $1.48 target or 7.00% below today’s $1.59 share price. Cardiome Pharma Corp. (CRME) has $56.51M valuation. The stock increased 1.27% or $0.02 during the last trading session, reaching $1.59. About 45,426 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since January 4, 2017 and is downtrending. It has underperformed by 27.72% the S&P500.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $1.08 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Analysts await Xencor, Inc. (NASDAQ:XNCR) to report earnings on February, 27. They expect $-0.34 EPS, down 61.90% or $0.13 from last year’s $-0.21 per share. After $-0.33 actual EPS reported by Xencor, Inc. for the previous quarter, Wall Street now forecasts 3.03% negative EPS growth.

The stock increased 0.53% or $0.12 during the last trading session, reaching $22.92. About 105,688 shares traded. Xencor, Inc. (XNCR) has risen 73.89% since January 4, 2017 and is uptrending. It has outperformed by 57.19% the S&P500.

Since January 1, 0001, it had 4 insider purchases, and 0 insider sales for $6.98 million activity.

Redmile Group Llc holds 1.36% of its portfolio in Xencor, Inc. for 1.20 million shares. Perceptive Advisors Llc owns 1.29 million shares or 1.13% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 0.73% invested in the company for 250,000 shares. The New York-based Deerfield Management Co has invested 0.54% in the stock. Eventide Asset Management Llc, a Massachusetts-based fund reported 313,000 shares.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.26, from 0.83 in 2017Q2. It is positive, as 2 investors sold Cardiome Pharma Corp. shares while 9 reduced holdings. 7 funds opened positions while 5 raised stakes. 13.54 million shares or 10.92% less from 15.20 million shares in 2017Q2 were reported. Citadel Advsrs Ltd Liability Corp accumulated 16,339 shares. Moreover, Royal Bank Of Canada has 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME). Westfield Capital Co Limited Partnership owns 4.86M shares. Rock Springs Capital Mngmt Limited Partnership holds 0.12% or 1.20M shares in its portfolio. Clough Cap Prtn Limited Partnership, a Massachusetts-based fund reported 2.88M shares. Alphaone Investment Lc has 600,625 shares. Moreover, Morgan Stanley has 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME). Jpmorgan Chase & Company accumulated 158,697 shares or 0% of the stock. Bancorporation Of Montreal Can has 1,004 shares. Massachusetts-based Geode Cap Mngmt Ltd Limited Liability Company has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Art Advisors Ltd Liability owns 16,718 shares for 0% of their portfolio. Virtu Lc stated it has 27,658 shares. Renaissance Technology Limited Liability holds 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME) for 411,413 shares. Pnc Gru owns 51,400 shares or 0% of their US portfolio. Ardsley Advisory Prtn invested in 36,200 shares.

Analysts await Cardiome Pharma Corp. (NASDAQ:CRME) to report earnings on March, 6. They expect $-0.19 EPS, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.20 actual EPS reported by Cardiome Pharma Corp. for the previous quarter, Wall Street now forecasts -5.00% EPS growth.